Table 1: Relationship of outcome to clinical parameters and molecular subtypes in cohort-1, the Oncomine-dataset, and TCGA.
Cohort-1 | ||||||
---|---|---|---|---|---|---|
Metastasis | CSS Indicator | |||||
Parameter | χ2 | P value | OR; 95% CI | χ2 | P value | OR; 95% CI |
Age | 0.02 | 0.885 | 0.49 | 0.484 | ||
Sex | 0.54 | 0.462 | 0.29 | 0.590 | ||
T-Stage | 7.17 | 0.007 | 1.2; 1.1 – 1.4 | 6.76 | 0.009 | 1.2; 1.04 – 1.3 |
N-stage | 5.15 | 0.023 | 7.5; 1.3 – 42.8 | 6.33 | 0.012 | 9.4; 1.6 – 53.6 |
CIS | 0 | 0.995 | 0 | 0.994 | ||
MCG-1 | 0.23 | 0.629 | 0.86 | 0.354 | ||
Oncomine-dataset | ||||||
CSS Indicator | OS Indicator | |||||
Parameter | χ2 | P value | OR; 95% CI | χ2 | P value | OR; 95% CI |
Age | 3.06 | 0.080 | 1.07 | 0.301 | ||
Sex | 0.02 | 0.894 | 0.06 | 0.806 | ||
T-stage | 11.43 | 0.0007 | 1.1; 1.04 – 1.2 | 9.2 | 0.002 | 1.1; 1.04 – 1.2 |
N-stage | 8.84 | 0.003 | 3.4; 1.5 – 7.5 | 1.55 | 0.213 | |
M-stage | 0 | 0.998 | 5.38 | 0.020 | 11.9; 1.5 – 96.1 | |
MCG-1 | 0.06 | 0.808 | 0.98 | 0.323 | ||
TCGA-dataset | ||||||
RFS Indicator | OS Indicator | |||||
Parameter | χ2 | P value | OR; 95% CI | χ2 | P value | OR; 95% CI |
Age | 0.17 | 0.682 | 15.5 | < 0.0001 | 1.04; 1.02 – 1.06 | |
Sex | 0 | 0.945 | 0.67 | 0.414 | ||
Grade | 3.67 | 0.056 | 7.44 | 0.006 | 7.8; 1.8 – 34.1 | |
T-stage | 4.23 | 0.04 | 1.04; 1.0 – 1.1 | 18.8 | < 0.0001 | 1.08; 1.04 – 1.1 |
N-stage | 13.95 | 0.0002 | 2.8; 1.6 – 4.9 | 31.1 | < 0.0001 | 3.6; 2.3 – 5.7 |
LVI | 3.16 | 0.076 | 11.8 | 0.0006 | 2.4; 1.5 – 3.9 | |
M-stage | 0.98 | 0.323 | 4.44 | 0.035 | 4.3; 1.1 – 16.8 | |
MCG-1 | 2.28 | 0.131 | 5.5 | 0.019 | 1.3; 1.04 – 1.5 | |
MCG-Ext | 0.68 | 0.410 | 8.36 | 0.004 | 1.3; 1.1 – 1.6 | |
Consensus | 4.78 | 0.029 | 1.2; 1.02 – 1.4 | 23.26 | < 0.0001 | 1.3; 1.2 – 1.5 |
TCGA-2017 | 0.98 | 0.323 | 10.65 | 0.001 | 1.4; 1.1 – 1.6 | |
Lund-Taxonomy | 1.1 | 0.294 | 8.05 | 0.005 | 1.3; 1.1 – 1.5 |